[1]SHIN AE,GIANCOTTI FG,RUSTGI AK.Metastatic colorectal cancer:Mechanisms and emerging therapeutics[J].Trends Pharmacol Sci,2023,44(4):222-236.
[2]FABREGAS JC,RAMNARAIGN B,GEORGE TJ.Clinical updates for colon cancer care in 2022[J].Clin Colorectal Cancer,2022,21(3):198-203.
[3]GMEINER WH,OKECHUKWU CC.Review of 5-FU resistance mechanisms in colorectal cancer:Clinical significance of attenuated on-target effects[J].Cancer Drug Resist,2023,6(2):257-272.
[4]谢竹夫,姚菲,吴清明.基于生物信息学和转录组测序分析结直肠癌5-FU耐药关键靶点[J].现代肿瘤医学,2022,30(23):4226-4232.
XIE ZF,YAO F,WU QM.Bioinformatics and transcriptome sequencing analysis of 5-FU resistance key targets in colorectal cancer[J].Modern Oncology,2022,30(23):4226-4232.
[5]BENDOVA P,PARDINI B,SUSOVA S,et al.Genetic variations in microRNA-binding sites of solute carrier transporter genes as predictors of clinical outcome in colorectal cancer[J].Carcinogenesis,2021,42(3):378-394.
[6]XIANG C,ZHANG ML,ZHAO QZ,et al.LncRNA-SLC6A9-5:A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction[J].Oncotarget,2017,8(14):22954-22967.
[7]VODENKOVA S,BUCHLER T,CERVENA K,et al.5-fluorouracil and other fluoropyrimidines in colorectal cancer:Past,present and future[J].Pharmacol Ther,2020,206:107447.
[8]HARRISON SA,MANGHI FP,SMITH WB,et al.Licogliflozin for nonalcoholic steatohepatitis:A randomized,double-blind,placebo-controlled,phase 2a study[J].Nat Med,2022,28(7):1432-1438.
[9]GYIMESI G,HEDIGER MA.Transporter-mediated drug delivery[J].Molecules,2023,28(3):1151.
[10]SCHLESSINGER A,ZATORSKI N,HUTCHINSON K,et al.Targeting SLC transporters:Small molecules as modulators and therapeutic opportunities[J].Trends Biochem Sci,2023,48(9):801-814.
[11]MYNOTT RL,WALLINGTON-BEDDOE CT.Drug and solute transporters in mediating resistance to novel therapeutics in multiple myeloma[J].ACS Pharmacol Transl Sci,2021,4(3):1050-1065.
[12]CHEN C,CAI Z,ZHUO Y,et al.Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer[J].BMC Cancer,2020,20(1):289.
[13]JANUCHOWSKI R,ZAWIERUCHA P,ANDRZEJEWSKA M,et al.Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines[J].Biomed Pharmacother,2013,67(3):240-245.
[14]KIM JE,HONG YS,KIM HJ,et al.Microsatellite instability was not associated with survival in stage Ⅲ colon cancer treated with adjuvant chemotherapy of oxaliplatin and infusional 5-fluorouracil and leucovorin(FOLFOX)[J].Ann Surg Oncol,2017,24(5):1289-1294.
[15]张晓林,吴浩松,汪盛.SLC12A8通过JAK/STAT途径促进膀胱癌细胞的增殖、侵袭与迁移并触发上皮间充质转化[J].南方医科大学学报,2023,43(9):1613-1621.
ZHANG XL,WU HS,WANG S.SLC12A8 promotes the proliferation, invasion and migration of bladder cancer cells through JAK/STAT pathway and triggers epithelial-mesenchymal transition[J].Journal of Southern Medical University,2023,43(9):1613-1621.
[16]PASTUSHENKO I,BLANPAIN C.EMT transition states during tumor progression and metastasis[J].Trends Cell Biol,2019,29(3):212-226.
[17]HUANG Y,HONG W,WEI X.The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis[J].J Hematol Oncol,2022,15(1):129.
[18]徐园园,唐清珠,邓加雄,等.AEBP1通过激活Wnt/β-catenin信号通路调控EMT促进结肠癌细胞增殖迁移[J].现代肿瘤医学,2021,29(14):2393-2400.
XU YY,TANG QZ,DENG JX,et al.AEBP1 promotes cell proliferation and migration through regulating EMT by activating Wnt/β-catenin pathway in colon cancer[J].Modern Oncology,2021,29(14):2393-2400.
[19]党锋,杨坤荣,刘文聘,等.柴胡皂苷D通过抑制EMT和细胞干性抑制人结直肠癌细胞SW480的迁移和侵袭[J].现代肿瘤医学,2020,28(7):1091-1096.
DANG F,YANG KR,LIU WP,et al.Saikosaponin-D inhibits cell migration and invasion via EMT and stemness suppression in colorectal cancer cell line SW480[J].Modern Oncology,2020,28(7):1091-1096.